Summary

Eligibility
for people ages 18-67 (full criteria)
Location
at San Francisco, California
Dates
study started
completion around
Principal Investigator
by Steven Deeks
Headshot of Steven Deeks
Steven Deeks

Description

Summary

Combination approaches will almost certainly be required to generate durable control of HIV in the absence of antiretroviral therapy (a "remission"). In this study, 20 individuals will receive a combination regimen administered during ART and then undergo an analytic treatment interruption (ATI).

Official Title

Combinatorial Therapy With a Therapeutic Conserved Element DNA Vaccine, MVA Vaccine Boost, TLR9 Agonist and Broadly Neutralizing Antibodies: a Proof-of-concept Study Aimed at Inducing an HIV Remission

Details

Keywords

HIV/AIDS, Acquired Immunodeficiency Syndrome, HIV Infections, Combination Intervention

Eligibility

Location

  • Zuckerberg San Francisco General Hospital, UCSF
    San Francisco California 94110 United States

Lead Scientist at UCSF

  • Steven Deeks
    Steven G. Deeks, MD, is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Division of HIV, Infectious Diseases and Global Medicine at Zuckerberg San Francisco General Hospital. He is an internationally recognized expert on HIV pathogenesis and treatment.

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT04357821
Phase
Phase 1/2 research study
Study Type
Interventional
Participants
About 11 people participating
Last Updated